There is a paradox at the heart of CBG’s biology. Throughout the plant’s life, cannabigerol works for everyone else: in its acid form, it is the precursor from which THC, CBD, and nearly all other known cannabinoids are derived. Once that task is complete, very little of it remains in the final product, typically less than 1% of the dry weight. This is the process that earned CBG the label of “the mother of all cannabinoids”: an accurate definition, but one that has ultimately reduced it to a footnote. The problem is that the footnote conceals a far more interesting story.
A pharmacological profile of its own
Unlike CBD, CBG partially binds to both CB1 and CB2 cannabinoid receptors, with an affinity for CB1 roughly twenty times lower than that of THC, enough to engage circuits that CBD alone does not reach with the same precision, without producing intoxication. It also acts on TRP channels and the serotonin receptor 5-HT1A, making it complementary to — and in some respects independent from — the other cannabinoids.
The first human clinical trial
In July 2024, Scientific Reports published the first controlled human study on the acute effects of CBG. Conducted by Washington State University in collaboration with UCLA, the trial showed that 20 mg of CBG significantly reduced anxiety and stress compared to placebo, with no adverse cognitive or motor effects. The most surprising finding: CBG improved participants’ ability to recall word sequences, a verbal memory enhancement that the researchers verified multiple times before accepting it as valid. The study’s limitations (small sample size, remote administration) call for caution, but it represents the first direct clinical evidence in humans.
One of the most unexpected areas of research concerns bacterial resistance. In a study comparing five cannabinoids, CBG demonstrated the most potent antibacterial activity against MRSA, the feared methicillin-resistant Staphylococcus aureus. It inhibited biofilm formation, eradicated so-called “persister” cells (dormant bacterial forms that are immune to conventional antibiotics), and in murine models showed efficacy comparable to vancomycin, the antibiotic of last resort. If confirmed in humans, this would place CBG among the most serious candidates in the search for alternatives to traditional antibiotics
The gut and the microbiome
CBG has also shown significant effects on inflammatory bowel diseases. A study from the University of Naples Federico II (Borrelli et al., 2013) documented in a murine model of colitis that the cannabinoid attenuated inflammation and reduced nitric oxide production in immune cells. More recent research, published in 2024 in the Journal of Pharmacology and Experimental Therapeutics, confirmed this effect in a different colitis model and added a new finding: treatment with a high-CBG hemp extract also positively modulated the composition of the gut microbiome.
Most studies on CBG remain at the animal or in vitro stage. The 2024 trial is an important first clinical step, not a destination. What can be stated with confidence is that CBG’s safety profile appears solid: no intoxication, no cognitive impairment, no significant adverse effects. CBG spent its existence donating its acid form to build the entire chemistry of cannabis. Now that research is beginning to study it for what it is — not just for what it has produced — the surprises may not be over.
Exclusive feature article created by World renown Cannabis Author & Authority Mario Catania for CBD Clinic Care International
